Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children

Key Points

• The aim is to evaluate the effectiveness of tocilizumab in treating severe CNS inflammatory presentations in children.
• Class IV evidence study design
• Assessment of clinical outcomes
• Population involved children with acute-severe CNS inflammation
• Tocilizumab improved clinical outcomes for children with severe CNS inflammation.
• The findings suggest a positive therapeutic effect of tocilizumab on acute severe events.

Abstract